Rivaroxaban vs. Vitamin K anatgonist in AF patients undergoing a PCI

• Research type

  Research Study

• Full title

  An Open-label, Randomized, Controlled, Multicenter Study ExplorIng Two Treatment Strategies of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention

• IRAS ID

  111263

• Contact name

  Gregory Lip

• Contact email

  g.y.h.lip@bham.ac.uk

• Sponsor organisation

  Janssen-Cilag International N.V

• Eudract number

  2012-001491-11

• ISRCTN Number

  n/a

• REC name

  London - Surrey Borders Research Ethics Committee

• REC reference

  13/LO/0528

• Date of REC Opinion

  10 May 2013

• REC opinion

  Further Information Favourable Opinion